• 30 April 2019

    Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, today announces that results from the first-in-human single dose DSR (Direct Sodium Removal) proof-of-concept study for volume overload in heart failure have been selected for oral presentation in the late-breaking abstract session at Heart Failure 2019 on 27 May 2019. Heart Failure 2019 will be held from 25 to 28 May 2019 in Athens, Greece and is the 6th World Congress on Acute Heart Failure organised by the Heart Failure Association of the European Society of Cardiology.

  • 25 April 2019

    Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today provided a corporate update, and reported cash and cash equivalents of 7.3 million, at March 31, 2019.

  • 12 April 2019

    X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today the pricing of its previously announced underwritten public offering of 5,670,000 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 2,130,000 shares of common stock, and accompanying Class A warrants to purchase 3,900,000 shares of its common stock at a price to the public of $11.00 per share and accompanying Class A warrant (or $10.999 per pre-funded warrant and accompanying Class A warrant). X4’s gross proceeds from this offering are expected to be approximately $85.8 million, before deducting underwriting discounts and estimated offering expenses. All of the securities in the offering are being sold by X4. The offering is expected to close on or about April 16, 2019, subject to customary closing conditions.

  • 11 April 2019

    InDex Pharmaceuticals Holding AB (publ) today announced that 197 patients, of the total 215 planned, have been enrolled to date in the CONDUCT study evaluating the drug candidate cobitolimod. The patient recruitment has varied significantly on a monthly basis, with between 6 and 19 patients enrolled, which makes it challenging to predict the remaining recruitment time. The company estimates that the patient recruitment will be completed during the month of June at the latest, which represents a delay compared to the previously communicated timeline. The company will announce when the last patient has been enrolled in the study and the top line results are expected to be available within 8-10 weeks thereafter.

  • 11 April 2019

    Sonendo, the manufacturer of the GentleWave System®, today reported that they had shipped more than 200,000 GentleWave Procedure Instruments.